Los Angeles Lakers forward LeBron James (foot) is available for Sunday's game against the Kings. The King had 22 points, nine assists, and seven boards in 28 minutes in the 129-101 win over the Golden State Warriors on Saturday. He popped up on the injury report because of the infamous foot issue. However, that won't keep him off the floor. James has a chance to do something meaningful for fantasy managers, considering Sacramento isn't the best defensively, although his overall contributions could be less than usual if the Lakers build a decisive lead throughout the contest.

New Orleans Pelicans forward Zion Williamson (ankle) won't play on Sunday versus the Clippers. The 25-year-old hasn't missed a game since mid-December. Unfortunately, he injured his ankle during Saturday's win over the Utah Jazz. His next opportunity to get on the floor will be on Tuesday versus the Lakers. Fortunately, Trey Murphy III (shoulder) will return from his five-game absence, which will help lessen the blow caused by Williamson's absence.

Utah Jazz forward/center Kevin Love (rest) is out for Monday's game against the Nuggets as the veteran sits for maintenance after playing in four straight contests. His absence should help lock in Kyle Filipowski's minutes in an already thin Utah frontcourt. Filipowski produced 12 points, six rebounds, one assist, one steal, and one block in 30 minutes last game and continues to log a steady run. With Utah prioritizing youth and dealing with multiple frontcourt injuries, Filipowski profiles as more than a streamer and should be viewed as a long-term hold in most formats.

Washington Wizards forward/center Tristan Vukcevic (thigh) is questionable for Monday's game against the Rockets as he continues to work through lower-body injuries. His minutes have been tightly managed of late, with his workload consistently capped, limiting his fantasy ceiling. Anthony Gill (illness), who posted eight points, five rebounds, and three assists in 28 minutes last game, could handle a larger workload if available. Vukcevic remains a high-risk option in standard formats given the unstable role and ongoing health concerns.